Migraine Drugs Market

Table of Contents

1 Introduction
    1.1 Objective of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered in the Study
    1.4 Stakeholders

2 Research Methodology
    2.1 Market Size Estimation
    2.2 Market Crackdown and Data Triangulation
    2.3 Market Share Estimation
           2.3.1 Key Data Points Taken From Secondary Sources
           2.3.2 Key Data Points Taken From Primary Sources
    2.4 Assumptions

3 Executive Summary

4 Premium Insights

5 Market Overview
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
           5.2.2 Restraints
           5.2.3 Opportunities
           5.2.4 Challenges

6 Migraine Drugs Market, By Product Type
    6.1 Introduction
    6.2 Acute Migraine Treatment
           6.2.1 Analgesic
           6.2.2 Ergotamine
           6.2.3 Triptans
    6.3 Preventive Migraine Treatment 
           6.3.1  Beta Blockers
           6.3.2 Anti-Serotonergic Drugs
           6.3.3 Antidepressants
           6.3.4  Anti-Convulsants
           6.3.5 Calcium Channel Blockers
           6.3.6 Others

7 Migraine Drugs Market, By Route of Administration
    7.1 Introduction
    7.2 Oral
    7.3 Injection
    7.4 Others

9 Migraine Drugs Market, By End User
    9.1 Introduction
    9.2 Hospitals Based Pharmacies
    9.3 Retail Pharmacies
    9.4 Online Pharmacies

10 Migraine Drugs Market, By Region
     10.1 Introduction
     10.2 North America
             10.2.1 US
             10.2.2 Canada
     10.3 Europe
             10.3.1 Germany
             10.3.2 UK
             10.3.3 France
             10.3.4 Rest of Europe (RoE)
     10.4 Asia Pacific
             10.4.1 China
             10.4.2 India
             10.4.3 Japan
             10.4.4 Rest of Asia Pacific
     10.5 Rest of the World (RoW)

11 Competitive Landscape
     11.1 Introduction
     11.2 Market Share Analysis
     11.3 Competitive Situation and Trends

12 Company Profiles*
     12.1 Introduction
     12.2 Abbott Labrotatories 
     12.3 Allergan 
     12.4 Amgen
     12.5 Glaxosmithkline
     12.6 Pfizer.
     12.7 Eli Lilly 
     12.8 Aegis Therapeutics, LLC.
     12.9 Johnson & Johnson
     12.10 Astrazeneca PLC

Note: *Details on Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.
* 10 to 15 Market Leaders Will Be Profiled
* Segmentation May Change During the Planned Research Work